In tropical developing regions, typhoid fever and malaria often co-occur, posing serious health risks. The two illnesses have similar symptoms, which makes diagnosis and treatment more difficult. Through a thorough analysis of existing literature on typhoid fever, malaria, and co-infection, including research articles, case studies, and review papers, this review seeks to understand the dynamic interactions between typhoid fever and malaria co-infection. The review highlights important problems with co-infection between typhoid and malaria, such as higher morbidity and death, diagnostics-related challenges, and antibiotic resistance. Overlapping symptoms and limitations in current diagnostic tests impede accuracy. Treatment plans are made more difficult by the advent of typhoid strains that are resistant to drugs. The analysis concludes by highlighting the necessity of developing more sensitive and specific diagnostic methods in order to accurately diagnose co-infections. Going forward, the review emphasizes the need for more investigation into the immunological connections between malaria and typhoid illnesses. Essentially, this paper offers a thorough summary of the difficulties and possibilities related to co-infection between typhoid and malaria. It provides a framework for upcoming studies and initiatives that seek to improve public health and patient outcomes in the face of these intricately linked health problems.
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is a major global pathogen with increasing resistance to conventional antibiotics. LL-37 and its derivative peptides have shown promising in vivo antibacterial activity. This study evaluated whether these peptides improve bacterial clearance, wound healing, and survival compared with controls in animal models of MRSA infection. Methods: The literature search was last updated on 21 April 2026. A systematic search of PubMed, Scopus, and Embase was conducted to identify preclinical studies assessing the antibacterial activity of LL-37 and its derivatives in MRSA animal infection models. Guided by PRISMA, 1,014 unique records were screened after removing 368 duplicates; 23 studies met the inclusion criteria, and 16 were included in the qualitative synthesis. Four studies (one comprising three independent experiments) provided sufficient data for meta-analysis. Extracted variables included sample size, bacterial counts (mean ± SD), and intervention/control details. Standardized mean differences (Hedges' g) were calculated using a random-effects model, and study quality was assessed using SYRCLE's risk-of-bias tool. Results: The meta-analysis of bacterial clearance pooled data from six independent experimental results (n = 44 animals). LL-37 and its derivatives achieved markedly greater bacterial eradication than controls, yielding a pooled standardized mean difference (SMD) of -7.86 (95% CI: -9.40 to -6.33; P < 0.001). All studies favoured LL-37, with no confidence intervals crossing zero. Heterogeneity was negligible (I² = 0%, τ² < 0.0001, P = 0.645), and the prediction interval (-9.74 to -5.99) indicated consistently large effects across similar experimental contexts. For wound healing (binary outcome), pooled analysis showed that LL-37 significantly increased complete wound closure rates compared with controls, with a pooled risk ratio (RR) of 1.25 (95% CI: 1.16-1.36). The pooled proportion of healed wounds was 89.3% in the LL-37 groups versus 70.0% in controls, indicating a clinically relevant improvement. Conclusions: LL-37 and its derivative peptides demonstrate robust antibacterial activity and significantly enhance wound healing in MRSA-infected animal models. The large and consistent effects observed across studies support their advancement toward translational research and early-phase clinical trials for potential human therapeutic use.
Salmonella Typhimurium is a typical Gram-Negative bacterium associated with food-borne illness threatening public health. This pathogen is reported to have caused millions of infections and thousands of hospitalizations yearly in the United States alone. Salmonella Typhimurium has a sophisticated array of virulent factors, including its flagella, which contributes significantly to its pathogenicity. Cannabidiol (CBD), the non-psychoactive component of the cannabis plant, has attracted the interest of many researchers recently because of its antimicrobial properties. With the growing interest in exploring CBD’s antimicrobial properties, we, in this study, have delved into unravelling how prolonged exposure of Salmonella Typhimurium to CBD influences the expression of the flgA gene. We hypothesized that the exposure of Salmonella Typhimurium to CBD may result in flgA upregulation, causing the bacteria to withstand various stresses and potentially enhance its survival rates and pathogenicity. We have employed several assays, such as mRNA expression, motility assays, pH induction assays, nutrient starvation interventions, and biofilm analysis, to explore the influence of CBD on the pathophysiology of Salmonella Typhimurium. Our findings reveal that CBD-resistant strains exhibit enhanced resilience to extreme pH levels and motility and survive poorly under nutrient starvation, with more robust biofilm formation compared to the susceptible strains. The results contribute to the broader comprehension of CBD resistance mechanisms in bacteria. This work provides insight into the potential therapeutic interventions for controlling CBD-resistant bacterial infections. This study also underscores the essence of exploring novel alternative antimicrobial agents to tackle the ever-persistence of bacterial antibiotic resistance.
Medicinal plants serve as valuable reservoirs of bioactive compounds with therapeutic potential, offering alternatives in the fight against drug-resistant infections. Hyptis suaveolens (L.) Poit., though widely used in traditional medicine, remains underexplored despite reports of antimicrobial, anti-inflammatory, and other pharmacological activities. Given the global need for novel antimicrobials, this study investigated the volatile (essential oils) and non-volatile (methanolic) extracts of H. suaveolens leaves, aiming to assess their antimicrobial activity against selected bacterial and fungal pathogens. Fresh Hyptis suaveolens leaves were collected and authenticated at Adekunle Ajasin University, Nigeria. Essential oils were obtained via hydro-distillation, while methanolic extracts were prepared by maceration. Antimicrobial activity against clinical isolates (E. coli, P. aeruginosa, B. cereus, K. pneumoniae, and C. albicans) was assessed using agar well diffusion, with MIC and MBC determined through macro-broth dilution techniques. Hydro-distillation of fresh leaves yielded 2.7% essential oil, while methanol extraction of dried leaves produced 1.5% crude extract. Both extracts inhibited all six clinical isolates, with the methanolic extract showing greater efficacy. The highest inhibition zone was recorded against Candida albicans (32 mm), and the lowest against Staphylococcus aureus (27 mm). Minimum inhibitory concentration (MIC) testing revealed consistent activity of the methanolic extract across all concentrations, whereas the essential oil displayed variable inhibition. Minimum bactericidal concentration (MBC) assays confirmed bactericidal activity of both extracts, with E. coli and Pseudomonas aeruginosa eradicated at 25–50 mg/mL, while Klebsiella pneumoniae required the highest concentration (12.5 mg/mL). Hyptis suaveolens extracts exhibited broad-spectrum antimicrobial and bactericidal activity, with methanolic extract showing superior potency, highlighting its potential as a natural alternative antimicrobial source.
The global rise of antimicrobial resistance necessitates the search for novel therapeutic agents from natural sources, particularly medicinal plants. Stereospermum kunthianum (Pink Jacaranda) has long been employed in traditional medicine for the treatment of infectious diseases; however, its antibacterial efficacy requires scientific validation. This study investigated the phytochemical constituents and antibacterial activity of stem bark extracts of S. kunthianum. The dried stem bark powder was sequentially extracted with hexane, ethyl acetate, acetone, and methanol using a Soxhlet apparatus. Phytochemical screening revealed the presence of tannins, flavonoids, alkaloids, saponins, terpenoids, phenols, steroids, cardiac glycosides, phlobatannins, and carbohydrates. Antibacterial activity was assessed against clinical isolates of Escherichia coli and Staphylococcus aureus, using standard bioassay methods. The extracts demonstrated variable antibacterial effects, with inhibition zones ranging from 5.0 to 17.0 mm. Ethyl acetate and methanol extracts exhibited the most pronounced activity, particularly against S. aureus and E. coli. Minimum inhibitory concentration (MIC) tests revealed that methanol extract inhibited S. aureus and E. coli at 12.5 mg/ml, while ethyl acetate extract inhibited S. aureus at 12.5 mg/ml and E. coli at 25 mg/ml. Although less potent than chloramphenicol (control), the findings affirm the antibacterial potential of S. kunthianum stem bark and provide scientific support for its ethnomedicinal use. These results highlight its promise as a source of bioactive compounds for drug discovery, warranting further investigation into its safety, mechanism of action, and potential for development into effective antimicrobial agents.